In this double-blind , placebo-controlled trial , we randomly assigned 558 hypertensive participants with ADPKD ( 15 to 49 years of age , with an estimated glomerular filtration rate [ GFR ] > 60 ml per minute per 1.73 m ( 2 ) of body-surface area ) to either a standard blood-pressure target ( 120/70 to 130/80 mm Hg ) or a low blood-pressure target ( 95/60 to 110/75 mm Hg ) and to either an angiotensin-converting-enzyme inhibitor ( lisinopril ) plus an angiotensin-receptor blocker ( telmisartan ) or lisinopril plus placebo .